Skip to main content

Table 2 Odds Ratio for Fracture, Indirect Treatment Comparison Results of Drug versus Placebo Classical and Bayesian analysis

From: The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

Classical analysis

Non-vertebral fracture

Vertebral fracture

Hip fracture

Wrist fracture

Drug vs placebo

OR (95% Cr I)

Placebo

rate

OR (95% Cr I)

Placebo

rate

OR (95% Cr I)

Placebo

rate

OR (95% Cr I)

Placebo

rate

Alendronate

0.80 (0.68, 0.95)

11.1%

0.51 (0.40, 0.63)

6.7%

0.62 (0.40, 0.96)

1.1%

0.44 (0.30, 0.67)

3.0%

Denosumab

0.80 (0.67, 0.96)

7.5%

0.31 (0.24, 0.40)

7.2%

0.60 (0.37, 0.98)

1.1%

NR

NR

Etidronate

0.64 (0.31, 1.32)

11.5%

0.59 (0.32, 1.10)

9.7%

0.60 (0.14, 2.66)

2.1%

1.19 (0.37, 3.80)

2.2%

Ibandronate

0.88 (0.71, 1.10)

7.5%

0.49 (0.32, 0.73)

7.5%

NR

NR

NR

NR

Raloxifene

0.91 (0.77, 1.07)

9.3%

0.63 (0.50, 0.78)

10.1%

1.12 (0.64, 1.95)

0.7%

0.88 (0.67, 1.15)

3.3%

Risedronate

0.79 (0.69, 0.89)

10.1%

0.59 (0.47, 0.75)

13.3%

0.74 (0.58, 0.94)

2.8%

0.71 (0.56, 0.89)

3.4%

Strontium

0.85 (0.74 (0.98)

14.7%

0.58 (0.50, 0.67)

21.7%

0.66 (1.19)

4.0%

1.59 (1.12, 2.27)

3.2%

Teriparatide

0.62 (0.40, 0.97)

9.7%

0.31 (0.19, 0.52)

14.3%

0.50 (0.09, 2.75)

0.7%

0.50 (0.09, 2.75)

2.4%

Zoledronic Acid

0.74 (0.63, 0.86)

10.0%

0.28 (0.22, 0.35)

10.9%

0.59 (0.83)

2.3%

NR

NR

All drugs vs placebo

0.81 (0.77, 0.86)

10.5%

0.49 (0.41, 0.58)

11.0%

0.73 (0.63, 0.84)

1.9%

0.82 (0.71, 0.94)

3.1%

Bayesian analysis

Non-vertebral fracture

Vertebral fracture

Hip fracture

Wrist fracture

Drug vs placebo

OR (95% Cr I)

Prob

Effect

size

OR (95% Cr I)

Prob

Effect

size

OR (95% Cr I)

Prob

Effect

size

OR (95% Cr I)

Prob

Effect

size

Alendronate

0.81 (0.66, 0.96)

0.01

16.1

0.51 (0.37, 0.68)

< 0.01

25.3

0.59 (0.29, 0.99)

0.10

9.49

0.93 (0.30, 2.64)

0.10

1.80

Denosumab

0.80 (0.60, 1.06)

0.03

10.7

0.31 (0.21, 0.44)

0.20

53.6

0.67 (0.24, 1.47)

0.12

4.76

NR

NR

NR

Etidronate

0.64 (0.31, 1.27)

0.42

6.4

0.61 (0.29, 1.08

0.01

8.3

1.02 (0.12, 3.91)

0.19

1.01

2.42 (0.25, 10.54)

0.06

0.16

Ibandronate

0.90 (0.69, 1.16)

< 0.01

9.3

0.50 (0.29, 0.78)

0.01

16.1

NR

NR

NR

NR

NR

NR

Raloxifene

0.91 (0.69, 1.20)

< 0.01

8.4

0.63 (0.43, 0.90)

0.00

13.4

1.29 (0.45, 2.88)

0.01

1.25

1.76 (0.09, 8.22)

0.15

0.27

Risedronate

0.77 (0.60, 0.91)

0.04

16.4

0.60 (0.45, 0.79)

0.00

19.3

0.78 (0.44, 1.32)

0.01

5.71

0.91 (0.13, 3.27)

0.22

1.37

Strontium

0.86 (0.69, 1.07)

< 0.01

12.0

0.59 (0.45, 0.76)

< 0.01

21.8

0.98 (0.39, 2.01)

0.01

2.47

3.25 (0.17, 14.89)

0.06

0.08

Teriparatide

0.62 (0.38, 1.02)

0.41

9.9

0.32 (0.17, 0.57)

0.30

29.8

0.71 (0.04, 2.90)

0.44

1.93

1.23 (0.05, 5.64)

0.41

0.57

Zoledronic Acid

0.74 (0.56, 0.97)

0.08

12.9

0.28 (0.19, 0.40)

0.40

66.2

0.65 (0.25, 1.34)

0.11

5.53

NR

NR

NR

  1. OR (95% Cr I): Odds ratio (95% Credibility Interval). Prob: probability of that drug being most efficacious.
  2. Effect size evaluated as Odds ratio divided by corresponding standard error. NR: Not reported.